Clinical uses of low-molecular-weight heparins

Chest

Volumn 115, Issue 5, 1999, Pages 1418-1423

  Aguilar, David ^a,b   Goldhabcr, Samuel Z ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Anticoagulation; Enoxaparin; Low molecular weight heparin; Pulmonary embolism; Thrombophlebitis; Unstable angina

Indexed keywords

ACETYLSALICYLIC ACID; ARDEPARIN; DALTEPARIN; DANAPAROID; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

DRUG INDICATION; DRUG SAFETY; EPIDURAL HEMATOMA; HEART VALVE PROSTHESIS; HEPARINIZATION; HUMAN; MOLECULAR WEIGHT; PARALYSIS; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW;

EID: 0032895135     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.115.5.1418     Document Type: Article

References (25)

1. Weitz JL. Low-molecular-weight heparins. N Engl J Med 1997; 337:688-698
2. Hirsh J. Low-inolecular-weight heparin: a review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. Circulation 1998; 98:1575-1582
3. Warkentin TE, Levine MM, Hirsh J, et al. Ileparin-induced throinbocytopenia in patients treated with low-molecularweight heparin or UFH. N Engl J Med 1995; 332:1330-1335
4. Monreal M, Lafoz E, Olive A, et al. Comparison of subcutaneous unfractionated heparin with low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71:7-11
5. Wysowski DK, Talarico L, Bacsanyi J, et al. Spinal and epidural heinatoma and low-inolecular-weight-heparin. N Engl J Med 1998; 338:1774
6. Cohen M, Deniers C, Gurfinkel E, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337:447-452
7. Mark DB, Couper PA, Berkowitz SD, et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Circulation 1998; 97:1702-1707
8. Montalescot G, Philippe F, Annick A, et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. Circulation 1998; 98:294-299
9. Antman EM, Handin R. Low-molecular-weight-heparins: an intriguing new twist with profound implications. Circulation 1998; 98:287-289
10. Antman EM, McCabe CH, Premmereur J, et al. Enoxaparin for the acute and chronic management of unstable angina/ non-Q-wave myocardial infarction: results of TIMI 11B. Circulation 1998; 98:1-504
11. Gecrts WH, Jay RM, Code Kl, et al. A comparison of low-dose lieparin with low-inolecular-weight heparin as prophylaxis against venous tlirombocmbolism after major trauma. N Engl J Med 1996; 335:701-706
12. Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998; 339:80-85
13. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326:975-982
14. Levine M, Gent M, Hirsh J, et al. A comparison of lowmolecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-681
15. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334:682-687
16. van den Belt AGM, Bossuyt PMM, Prins Mil, et al. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis-an economic evaluation. Thromb I lacmost 1998; 79:259-263
17. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, et al. Adjusted versus fixed doses of the low-molecular-weight heparin Fragmin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 71:698-702
18. Lindmarker P, Holmström M, Granqvist S, et id. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromh Haemost 1994; 72:186-190
19. Fiessinger JN, Lopez-Fernandez M, Gatterer E, et al. Oncedaily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996; 76:195-199
20. Goldhaber SZ, Morrison RB, Drain LL, et al. Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin. Arch Intern Med 199S; 158:2325-2328
21. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337:657-662
22. Simonneau G, Sors II, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337:663-669
23. Zidar JP. Low-molecular-weight heparin in coronary stenting (the ENTICES trial). Am J Cardiol 1998; 82:29L-32L
24. Hunt BJ, Doughty HA, Majumdar G, et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high-risk pregnancies. Thromb Haemost 1997; 77:39-43
25. Bonow RO, Carabello B, de Leon AC Jr, et al. ACC/AHA guidelines for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease). Circulation 1998; 98:1949-1984